Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole

Journal of Clinical Microbiology

Volumn 45, Issue 3, 2007, Pages 858-864

  Espinel Ingroff, A ^a   Canton, E ^b   Gibbs, D ^c   Wang, A ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c Giles Scientific Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASSAY; CANDIDA; CLINICAL LABORATORY; CORRELATION ANALYSIS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; DRUG SENSITIVITY; FUNGUS CULTURE; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; PYRIMIDINES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; TRIAZOLES;

CANDIDA; FILOBASIDIELLA NEOFORMANS;

EID: 33947281751     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01900-06     Document Type: Article

References (22)

1. Barchiesi, F., E. Spreghini, S. Tomassetti, A. D. Vittoria, D. Arzeni, E. Manso, and G. Scalise. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimiciob. Agents Chemother. 50:2719-2727.
2. Cantón, E., J. Pemán, A. Carrillo-Muñoz, A. Orero, P. Ubeda, A. Viudes, and M. Gobernado. 1999. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. J. Clin. Microbiol. 37: 2197-2200.
3. Casals, J. B. 1979. Tablet sensitivity testing of pathogenic fungi. J. Clin. Pathol. 32:719-722.
4. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution susceptibility testing of yeasts: approved standard, 2nd ed. Document M27-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline. Document M44-A. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2006. Quality control minimal inhibitory concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints. Supplement M27-S2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2006. Zone diameter interpretive standards and corresponding minimal inhibitory concentration (MIC) interpretive breakpoints. Supplement M44-S1. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Espinel-Ingroff, A. 1988. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
9. Espinel-Ingroff, A. 2006. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J. Clin. Microbiol. 44: 3616-3622.
10. Lozano-Chiu, M., P. W. Nelson, M. Lancaster, M. A. Pfaller, and J. H. Rex. 1997. Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. J. Clin. Microbiol. 35:270-272.
11. Lozano-Chiu, M., P. W. Nelson, V. L. Paetznick, and J. H. Rex. 1999. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J. Clin. Microbiol. 37:1625-1627.
12. Matar, M. J., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2003. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47:1647-1651.
13. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J.-L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
14. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamil, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
15. Park, B. J., B. A. Arthington-Skaggs, R. A. Hajjeh, N. Iqbal, M. A. Ciblak, W. Lee-Yang, M. D. Hairston, M. Phelan, B. D. Plikaytis, A. N. Sofair, L. H. Harrison, S. K. Fridkin, and D. W. Warnock. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50:1287-1292.
16. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
17. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis. 2003. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program. J. Clin. Microbiol. 41:1440-1446.
18. Pfaller, M. A., D. J. Diekema, M. G. Rinaldi, R. Barnes, B. Hu, A. V. Veselov, N. Tiraboschi, E. Nagy, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2005. Results from the ARTEMIS disk global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43:5848-5859.
19. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Evaluation of NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole. J. Clin. Microbiol. 42:380-383.
20. Rubio, M. C., J. Gil, I. Ramirez de Ocariz, R. Benito, and A. Rezusta. 2003. Comparison of results obtained by testing with three different agar media and by the NCCLS M27-A method for in vitro testing of fluconazole against Candida spp. J. Clin. Microbiol. 41:2665-2668.
21. Sandven, P. 1999. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test. J. Clin. Microbiol. 37:3856-3859.
22. Vandenbossche, I., M. Vaneechoutte, M. Vandevenne, T. De Baere, and G. Verschraegen. 2002. Susceptibility testing of fluconazole by the NCCLS broth microdilution method, E-test, and disk diffusion for application in the routine laboratory. J. Clin. Microbiol. 40:918-921.